219 related articles for article (PubMed ID: 19857450)
21. Expression of the herpes simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation of its immunogenicity in guinea pigs.
Fotouhi F; Soleimanjahi H; Roostaee MH; Dalimi Asl A
Iran Biomed J; 2008 Apr; 12(2):59-66. PubMed ID: 18506211
[TBL] [Abstract][Full Text] [Related]
22. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
23. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
Stanfield BA; Bravo FJ; Dixon DA; Chouljenko VN; Kousoulas KG; Bernstein DI
Vaccine; 2022 Oct; 40(42):6093-6099. PubMed ID: 36114130
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4
Srivastava R; Roy S; Coulon PG; Vahed H; Prakash S; Dhanushkodi N; Kim GJ; Fouladi MA; Campo J; Teng AA; Liang X; Schaefer H; BenMohamed L
J Virol; 2019 May; 93(9):. PubMed ID: 30787156
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
26. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
[TBL] [Abstract][Full Text] [Related]
28. Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs.
Awasthi S; Onishi M; Lubinski JM; Fowler BT; Naughton AM; Hook LM; Egan KP; Hagiwara M; Shirai S; Sakai A; Nakagawa T; Goto K; Yoshida O; Stephens AJ; Choi G; Cohen GH; Katayama K; Friedman HM
Viruses; 2023 May; 15(5):. PubMed ID: 37243234
[TBL] [Abstract][Full Text] [Related]
29. Optimized DNA Vaccine Enhanced by Adjuvant IL28B Induces Protective Immune Responses Against Herpes Simplex Virus Type 2 in Mice.
Zhou Y; Wang Z; Xu Y; Zhang Z; Hua R; Liu W; Jiang C; Chen Y; Yang W; Kong W
Viral Immunol; 2017 Oct; 30(8):601-614. PubMed ID: 28650722
[TBL] [Abstract][Full Text] [Related]
30. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection.
Bernstein DI; Tepe ER; Mester JC; Arnold RL; Stanberry LR; Higgins T
Vaccine; 1999 Apr; 17(15-16):1964-9. PubMed ID: 10217595
[TBL] [Abstract][Full Text] [Related]
31. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.
Morello CS; Levinson MS; Kraynyak KA; Spector DH
J Virol; 2011 Apr; 85(7):3461-72. PubMed ID: 21270160
[TBL] [Abstract][Full Text] [Related]
32. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
[TBL] [Abstract][Full Text] [Related]
33. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
Awasthi S; Shaw C; Friedman H
Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
[TBL] [Abstract][Full Text] [Related]
34. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597
[TBL] [Abstract][Full Text] [Related]
35. A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.
Veselenak RL; Shlapobersky M; Pyles RB; Wei Q; Sullivan SM; Bourne N
Vaccine; 2012 Nov; 30(49):7046-51. PubMed ID: 23041125
[TBL] [Abstract][Full Text] [Related]
36. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.
Skoberne M; Cardin R; Lee A; Kazimirova A; Zielinski V; Garvie D; Lundberg A; Larson S; Bravo FJ; Bernstein DI; Flechtner JB; Long D
J Virol; 2013 Apr; 87(7):3930-42. PubMed ID: 23365421
[TBL] [Abstract][Full Text] [Related]
37. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.
Harrison CJ; Miller RL; Bernstein DI
Vaccine; 2001 Feb; 19(13-14):1820-6. PubMed ID: 11166907
[TBL] [Abstract][Full Text] [Related]
38. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
Brans R; Yao F
BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
[TBL] [Abstract][Full Text] [Related]
39. Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.
Awasthi S; Hook LM; Swaminathan G; Cairns TM; Brooks B; Smith JS; Ditto NT; Gindy ME; Bett AJ; Espeseth AS; Cohen GH; Friedman HM
Vaccine; 2019 Jun; 37(29):3770-3778. PubMed ID: 31153687
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
